Frontiers of Medicine

, Volume 11, Issue 2, pp 284–286 | Cite as

Arsenic trioxide induced rhabdomyolysis, a rare but severe side effect, in an APL patient: a case report

  • Haiyan He
  • Ran An
  • Jian Hou
  • Weijun Fu
Case Report


Arsenic trioxide (ATO), a component of the traditional Chinese medicine arsenic sublimate, promotes apoptosis and induces leukemic cell differentiation. Combined with all-trans-retinotic acid (ATRA), ATO has become the first-line induction therapy in treating acute promyelocytic leukemia (APL). The most common side effects of ATO include hepatotoxicity, gastrointestinal symptoms, water-sodium retention, and nervous system damage. In this report, we present a rare side effect, rhabdomyolysis, in a 68-year-old female APL patient who was treated with ATO. After taking 10 mg ATO daily for 6 days, she presented shortness of breath, myodynia, elevated creatine kinase, and acute renal insufficiency. This report describes the first case of ATO-induced rhabdomyolysis.


arsenic trioxide APL rhabdomyolysis 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Chen Z, Chen SJ. RARA and PML genes in acute promyelocytic leukemia. Leuk Lymphoma 1992; 8(4-5): 253–260CrossRefPubMedGoogle Scholar
  2. 2.
    Zhang TD, Chen GQ, Wang ZG, Wang ZY, Chen SJ, Chen Z. Arsenic trioxide, a therapeutic agent for APL. Oncogene 2001; 20(49): 7146–7153CrossRefPubMedGoogle Scholar
  3. 3.
    Soignet SL, Frankel SR, Douer D, Tallman MS, Kantarjian H, Calleja E, Stone RM, Kalaycio M, Scheinberg DA, Steinherz P, Sievers EL, Coutré S, Dahlberg S, Ellison R, Warrell RP Jr. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol 2001; 19(18): 3852–3860CrossRefPubMedGoogle Scholar
  4. 4.
    Estey E, Garcia-Manero G, Ferrajoli A, Faderl S, Verstovsek S, Jones D, Kantarjian H. Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia. Blood 2006; 107(9): 3469–3473CrossRefPubMedGoogle Scholar
  5. 5.
    Ghavamzadeh A, Alimoghaddam K, Ghaffari SH, Rostami S, Jahani M, Hosseini R, Mossavi A, Baybordi E, Khodabadeh A, Iravani M, Bahar B, Mortazavi Y, Totonchi M, Aghdami N. Treatment of acute promyelocytic leukemia with arsenic trioxide without ATRA and/or chemotherapy. Ann Oncol 2006; 17(1): 131–134CrossRefPubMedGoogle Scholar
  6. 6.
    Fanton L, Duperret S, Guillaumée F, Miras A, Vallon JJ, Malicier D. Fatal rhabdomyolysis in arsenic trioxide poisoning. Hum Exp Toxicol 1999; 18(10): 640–641CrossRefPubMedGoogle Scholar
  7. 7.
    Zimmerman JL, Shen MC. Rhabdomyolysis. Chest 2013; 144(3): 1058–1065CrossRefPubMedGoogle Scholar
  8. 8.
    Moscetti L, Nelli F, Ruggeri EM. Rhabdomyolysis from erlotinib: a case report. Tumori 2011; 97(3): 415–416CrossRefPubMedGoogle Scholar
  9. 9.
    Ruggeri EM, Cecere FL, Moscetti L, Doni L, Padalino D, Di Costanzo F. Severe rhabdomyolysis during sunitinib treatment of metastatic renal cell carcinoma: a report of two cases. Ann Oncol 2010; 21(9): 1926–1927CrossRefPubMedGoogle Scholar
  10. 10.
    Quezada G, Kopp L, Estey E, Wells RJ. All-trans-retinoic acid and arsenic trioxide as initial therapy for acute promyelocytic leukemia. Pediatr Blood Cancer 2008; 51(1): 133–135CrossRefPubMedGoogle Scholar
  11. 11.
    Rogers JE, Yang D. Differentiation syndrome in patients with acute promyelocytic leukemia. J Oncol Pharm Pract 2012; 18(1): 109–114CrossRefPubMedGoogle Scholar
  12. 12.
    Mendila M, Walter GF, Stoll M, Schmidt RE. Rhabdomyolysis in antiretroviral therapy with Lamivudin. Dtsch Med Wochenschr 1997; 122(33): 1003–1006CrossRefPubMedGoogle Scholar

Copyright information

© Higher Education Press and Springer-Verlag Berlin Heidelberg 2017

Authors and Affiliations

  1. 1.Myeloma and Lymphoma Center, Department of HematologyChangzheng HospitalShanghaiChina

Personalised recommendations